{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PI3K/Akt/mTOR signaling pathway", "T cell", "Tumor microenvironment", "cancer", "immune response", "mTOR"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35250965", "DateCompleted": {"Year": "2022", "Month": "05", "Day": "02"}, "DateRevised": {"Year": "2022", "Month": "05", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "02", "Day": "18"}], "Language": ["eng"], "ELocationID": ["774103", "10.3389/fimmu.2021.774103"], "Journal": {"ISSN": "1664-3224", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2021"}}, "Title": "Frontiers in immunology", "ISOAbbreviation": "Front Immunol"}, "ArticleTitle": "mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.", "Pagination": {"StartPage": "774103", "MedlinePgn": "774103"}, "Abstract": {"AbstractText": ["The mechanistic/mammalian target of rapamycin (mTOR) is a downstream mediator in the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways, which plays a pivotal role in regulating numerous cellular functions including cell growth, proliferation, survival, and metabolism by integrating a variety of extracellular and intracellular signals in the tumor microenvironment (TME). Dysregulation of the mTOR pathway is frequently reported in many types of human tumors, and targeting the PI3K/Akt/mTOR signaling pathway has been considered an attractive potential therapeutic target in cancer. The PI3K/Akt/mTOR signaling transduction pathway is important not only in the development and progression of cancers but also for its critical regulatory role in the tumor microenvironment. Immunologically, mTOR is emerging as a key regulator of immune responses. The mTOR signaling pathway plays an essential regulatory role in the differentiation and function of both innate and adaptive immune cells. Considering the central role of mTOR in metabolic and translational reprogramming, it can affect tumor-associated immune cells to undergo phenotypic and functional reprogramming in TME. The mTOR-mediated inflammatory response can also promote the recruitment of immune cells to TME, resulting in exerting the anti-tumor functions or promoting cancer cell growth, progression, and metastasis. Thus, deregulated mTOR signaling in cancer can modulate the TME, thereby affecting the tumor immune microenvironment. Here, we review the current knowledge regarding the crucial role of the PI3K/Akt/mTOR pathway in controlling and shaping the immune responses in TME."], "CopyrightInformation": "Copyright \u00a9 2022 Mafi, Mansoori, Taeb, Sadeghi, Abbasi, Cho and Rostamzadeh."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Yasuj University of Medical Sciences, Yasuj, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Mafi", "ForeName": "Sahar", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Wistar Institute, Molecular & Cellular Oncogenesis Program, Philadelphia, PA, United States."}], "LastName": "Mansoori", "ForeName": "Behzad", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran."}, {"Identifier": [], "Affiliation": "Medical Biotechnology Research Center, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran."}], "LastName": "Taeb", "ForeName": "Shahram", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Sadeghi", "ForeName": "Hossein", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Abbasi", "ForeName": "Reza", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR, China."}], "LastName": "Cho", "ForeName": "William C", "Initials": "WC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Yasuj University of Medical Sciences, Yasuj, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Rostamzadeh", "ForeName": "Davoud", "Initials": "D"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Immunol", "NlmUniqueID": "101560960", "ISSNLinking": "1664-3224"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.1.1", "NameOfSubstance": "MTOR protein, human"}, {"RegistryNumber": "EC 2.7.1.137", "NameOfSubstance": "Phosphatidylinositol 3-Kinase"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "TOR Serine-Threonine Kinases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Immunity"}, {"QualifierName": ["immunology"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinase"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}, {"QualifierName": ["metabolism"], "DescriptorName": "TOR Serine-Threonine Kinases"}, {"QualifierName": ["immunology"], "DescriptorName": "Tumor Microenvironment"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Conciatori F, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, et al. . Role of mTOR Signaling in Tumor Microenvironment: An Overview. Int J Mol Sci (2018) 19:2453\u201367. doi: 10.3390/ijms19082453", "ArticleIdList": ["10.3390/ijms19082453", "PMC6121402", "30126252"]}, {"Citation": "Nazari N, Jafari F, Ghalamfarsa G, Hadinia A, Atapour A, Ahmadi M, et al. . The Emerging Role of microRNA in Regulating the mTOR Signaling Pathway in Immune and Inflammatory Responses. Immunol Cell Biol (2021) 99:814\u201332. doi: 10.1111/imcb.12477", "ArticleIdList": ["10.1111/imcb.12477", "33988889"]}, {"Citation": "Huang K, Fingar DC. Growing Knowledge of the mTOR Signaling Network. Semin Cell Dev Biol (2014) 36:79\u201390. doi: 10.1016/j.semcdb.2014.09.011", "ArticleIdList": ["10.1016/j.semcdb.2014.09.011", "PMC4253687", "25242279"]}, {"Citation": "Sabatini DM. mTOR and Cancer: Insights Into a Complex Relationship. Nat Rev Cancer (2006) 6:729. doi: 10.1038/nrc1974", "ArticleIdList": ["10.1038/nrc1974", "16915295"]}, {"Citation": "Dancey J. mTOR Signaling and Drug Development in Cancer. Nat Rev Clin Oncol (2010) 7:209\u201319. doi: 10.1038/nrclinonc.2010.21", "ArticleIdList": ["10.1038/nrclinonc.2010.21", "20234352"]}, {"Citation": "Mossmann D, Park S, Hall MN. mTOR Signalling and Cellular Metabolism are Mutual Determinants in Cancer. Nat Rev Cancer (2018) 18:744\u201357. doi: 10.1038/s41568-018-0074-8", "ArticleIdList": ["10.1038/s41568-018-0074-8", "30425336"]}, {"Citation": "Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K Pathway in Cancer: Are We Making Headway? Nat Rev Clin Oncol (2018) 15:273. doi: 10.1038/nrclinonc.2018.28", "ArticleIdList": ["10.1038/nrclinonc.2018.28", "29508857"]}, {"Citation": "Kaymak I, Williams KS, Cantor JR, Jones RG. Immunometabolic Interplay in the Tumor Microenvironment. Cancer Cell (2020) 1:28\u201337. doi: 10.1016/j.ccell.2020.09.004", "ArticleIdList": ["10.1016/j.ccell.2020.09.004", "PMC7837268", "33125860"]}, {"Citation": "Zhang XC, Wang J, Shao GG, Wang Q, Qu X, Wang B, et al. . Comprehensive Genomic and Immunological Characterization of Chinese Non-Small Cell Lung Cancer Patients. Nat Commun (2019) 10:1772. doi: 10.1038/s41467-019-09762-1", "ArticleIdList": ["10.1038/s41467-019-09762-1", "PMC6467893", "30992440"]}, {"Citation": "Jin J, Zhao Q. Emerging Role of mTOR in Tumor Immune Contexture: Impact on Chemokine-Related Immune Cells Migration. Theranostics (2020) 10:6231\u201344. doi: 10.7150/thno.45219", "ArticleIdList": ["10.7150/thno.45219", "PMC7255024", "32483450"]}, {"Citation": "Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and Tumor Cell Plasticity: An Easy Way Out. Cancer Lett (2013) 341:80\u201396. doi: 10.1016/j.canlet.2013.01.042", "ArticleIdList": ["10.1016/j.canlet.2013.01.042", "23376253"]}, {"Citation": "Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of Immune Responses by mTOR. Annu Rev Immunol (2012) 30:39\u201368. doi: 10.1146/annurev-immunol-020711-075024", "ArticleIdList": ["10.1146/annurev-immunol-020711-075024", "PMC3616892", "22136167"]}, {"Citation": "Rostamzadeh D, Yousefi M, Haghshenas MR, Ahmadi M, Dolati S, Babaloo Z. mTOR Signaling Pathway as a Master Regulator of Memory CD8(+) T-Cells, Th17, and NK Cells Development and Their Functional Properties. J Cell Physiol (2019) 234:12353\u201368. doi: 10.1002/jcp.28042", "ArticleIdList": ["10.1002/jcp.28042", "30710341"]}, {"Citation": "Kim LC, Cook RS, Chen J. Mtorc1 and Mtorc2 in Cancer and the Tumor Microenvironment. Oncogene (2017) 36:2191\u2013201. doi: 10.1038/onc.2016.363", "ArticleIdList": ["10.1038/onc.2016.363", "PMC5393956", "27748764"]}, {"Citation": "Li N, Chen J, Liu Q, Qu H, Yang X, Gao P, et al. . Prognostic Significance and Tumor-Immune Infiltration of mTOR in Clear Cell Renal Cell Carcinoma. PeerJ (2021) 9:e11901. doi: 10.7717/peerj.11901", "ArticleIdList": ["10.7717/peerj.11901", "PMC8378334", "34458019"]}, {"Citation": "Laplante M, Sabatini DM. mTOR Signaling at a Glance. J Cell Sci (2009) 122:3589\u201394. doi: 10.1242/jcs.051011", "ArticleIdList": ["10.1242/jcs.051011", "PMC2758797", "19812304"]}, {"Citation": "Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol (2014) 4:64. doi: 10.3389/fonc.2014.00064", "ArticleIdList": ["10.3389/fonc.2014.00064", "PMC3995050", "24782981"]}, {"Citation": "Manning BD, Cantley LC. Rheb Fills a GAP Between TSC and TOR. Trends Biochem Sci (2003) 28:573\u20136. doi: 10.1016/j.tibs.2003.09.003", "ArticleIdList": ["10.1016/j.tibs.2003.09.003", "14607085"]}, {"Citation": "Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase Is a Direct Target of TSC2 GAP Activity and Regulates mTOR Signaling. Genes Dev (2003) 17:1829\u201334. doi: 10.1101/gad.1110003", "ArticleIdList": ["10.1101/gad.1110003", "PMC196227", "12869586"]}, {"Citation": "Huang J, Manning BD. The TSC1-TSC2 Complex: A Molecular Switchboard Controlling Cell Growth. Biochem J (2008) 412:179\u201390. doi: 10.1042/BJ20080281", "ArticleIdList": ["10.1042/BJ20080281", "PMC2735030", "18466115"]}, {"Citation": "Wullschleger S, Loewith R, Hall MN. TOR Signaling in Growth and Metabolism. Cell (2006) 124:471\u201384. doi: 10.1016/j.cell.2006.01.016", "ArticleIdList": ["10.1016/j.cell.2006.01.016", "16469695"]}, {"Citation": "Laplante M, Sabatini DM. mTOR Signaling in Growth Control and Disease. Cell (2012) 149:274\u201393. doi: 10.1016/j.cell.2012.03.017", "ArticleIdList": ["10.1016/j.cell.2012.03.017", "PMC3331679", "22500797"]}, {"Citation": "Fruman DA, Limon JJ. Akt and mTOR in B Cell Activation and Differentiation. Front Immunol (2012) 3:228. doi: 10.3389/fimmu.2012.00228", "ArticleIdList": ["10.3389/fimmu.2012.00228", "PMC3412259", "22888331"]}, {"Citation": "Nascimento EB, Snel M, Guigas B, van der Zon GC, Kriek J, Maassen JA, et al. . Phosphorylation of PRAS40 on Thr246 by PKB/AKT Facilitates Efficient Phosphorylation of Ser183 by Mtorc1. Cell Signal (2010) 22:961\u20137. doi: 10.1016/j.cellsig.2010.02.002", "ArticleIdList": ["10.1016/j.cellsig.2010.02.002", "20138985"]}, {"Citation": "Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a New Antifungal Antibiotic. I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle. J Antibiot (Tokyo) (1975) 28:721\u20136. doi: 10.7164/antibiotics.28.721", "ArticleIdList": ["10.7164/antibiotics.28.721", "1102508"]}, {"Citation": "Chen Y, Zhou X. Research Progress of mTOR Inhibitors. Eur J Medicinal Chem (2020) 208:112820. doi: 10.1016/j.ejmech.2020.112820", "ArticleIdList": ["10.1016/j.ejmech.2020.112820", "32966896"]}, {"Citation": "Inoki K, Kim J, Guan KL. AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets. Annu Rev Pharmacol Toxicol (2012) 52:381\u2013400. doi: 10.1146/annurev-pharmtox-010611-134537", "ArticleIdList": ["10.1146/annurev-pharmtox-010611-134537", "22017684"]}, {"Citation": "Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. . TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth. Cell (2006) 126:955\u201368. doi: 10.1016/j.cell.2006.06.055", "ArticleIdList": ["10.1016/j.cell.2006.06.055", "16959574"]}, {"Citation": "Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian Cell Size Is Controlled by mTOR and its Downstream Targets S6K1 and 4EBP1/Eif4e. Genes Dev (2002) 16:1472\u201387. doi: 10.1101/gad.995802", "ArticleIdList": ["10.1101/gad.995802", "PMC186342", "12080086"]}, {"Citation": "Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. . Mtorc1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs. Science (2010) 328:1172\u20136. doi: 10.1126/science.1187532", "ArticleIdList": ["10.1126/science.1187532", "PMC2893390", "20508131"]}, {"Citation": "Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. . Prolonged Rapamycin Treatment Inhibits Mtorc2 Assembly and Akt/PKB. Mol Cell (2006) 22:159\u201368. doi: 10.1016/j.molcel.2006.03.029", "ArticleIdList": ["10.1016/j.molcel.2006.03.029", "16603397"]}, {"Citation": "Oh WJ, Jacinto E. mTOR Complex 2 Signaling and Functions. Cell Cycle (2011) 10:2305\u201316. doi: 10.4161/cc.10.14.16586", "ArticleIdList": ["10.4161/cc.10.14.16586", "PMC3322468", "21670596"]}, {"Citation": "Sparks CA, Guertin DA. Targeting mTOR: Prospects for mTOR Complex 2 Inhibitors in Cancer Therapy. Oncogene (2010) 29:3733\u201344. doi: 10.1038/onc.2010.139", "ArticleIdList": ["10.1038/onc.2010.139", "PMC3031870", "20418915"]}, {"Citation": "Yang G, Murashige DS, Humphrey SJ, James DE. A Positive Feedback Loop Between Akt and Mtorc2 via SIN1 Phosphorylation. Cell Rep (2015) 12:937\u201343. doi: 10.1016/j.celrep.2015.07.016", "ArticleIdList": ["10.1016/j.celrep.2015.07.016", "26235620"]}, {"Citation": "Bakker WJ, Harris IS, Mak TW. FOXO3a is Activated in Response to Hypoxic Stress and Inhibits HIF1-Induced Apoptosis via Regulation of CITED2. Mol Cell (2007) 28:941\u201353. doi: 10.1016/j.molcel.2007.10.035", "ArticleIdList": ["10.1016/j.molcel.2007.10.035", "18158893"]}, {"Citation": "Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. . mTOR Target NDRG1 Confers MGMT-Dependent Resistance to Alkylating Chemotherapy. Proc Natl Acad Sci USA (2014) 111:409\u201314. doi: 10.1073/pnas.1314469111", "ArticleIdList": ["10.1073/pnas.1314469111", "PMC3890826", "24367102"]}, {"Citation": "Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S, et al. . PRR5L Degradation Promotes Mtorc2-Mediated PKC-Delta Phosphorylation and Cell Migration Downstream of Galpha12. Nat Cell Biol (2012) 14:686\u201396. doi: 10.1038/ncb2507", "ArticleIdList": ["10.1038/ncb2507", "PMC3389271", "22609986"]}, {"Citation": "Thomanetz V, Angliker N, Cloetta D, Lustenberger RM, Schweighauser M, Oliveri F, et al. . Ablation of the Mtorc2 Component Rictor in Brain or Purkinje Cells Affects Size and Neuron Morphology. J Cell Biol (2013) 201:293\u2013308. doi: 10.1083/jcb.201205030", "ArticleIdList": ["10.1083/jcb.201205030", "PMC3628512", "23569215"]}, {"Citation": "Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of Mtorc2 by Association With the Ribosome. Cell (2011) 144:757\u201368. doi: 10.1016/j.cell.2011.02.014", "ArticleIdList": ["10.1016/j.cell.2011.02.014", "21376236"]}, {"Citation": "Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 2(7):489\u2013501. doi: 10.1038/nrc839", "ArticleIdList": ["10.1038/nrc839", "12094235"]}, {"Citation": "Joly MM, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, et al. . Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Res (2016) 76:4752\u201364. doi: 10.1158/0008-5472.CAN-15-3393", "ArticleIdList": ["10.1158/0008-5472.CAN-15-3393", "PMC5758362", "27197158"]}, {"Citation": "Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, et al. . RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. Cancer Discovery (2015) 5(12):1262\u201370. doi: 10.1158/2159-8290.CD-14-0971", "ArticleIdList": ["10.1158/2159-8290.CD-14-0971", "PMC4670806", "26370156"]}, {"Citation": "Gkountakos A, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M, et al. . Unmasking the Impact of Rictor in Cancer: Novel Insights of Mtorc2 Complex. Carcinogenesis (2018) 39:971\u201380. doi: 10.1093/carcin/bgy086", "ArticleIdList": ["10.1093/carcin/bgy086", "29955840"]}, {"Citation": "Mukohara T. PI3K Mutations in Breast Cancer: Prognostic and Therapeutic Implications. Breast Cancer (Dove Med Press) (2015) 7:111\u201323. doi: 10.2147/BCTT.S60696", "ArticleIdList": ["10.2147/BCTT.S60696", "PMC4440424", "26028978"]}, {"Citation": "Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, et al. . PIK3CA Mutations can Initiate Pancreatic Tumorigenesis and are Targetable with PI3K Inhibitors. Oncogenesis (2015) 4:e169. doi: 10.1038/oncsis.2015.28", "ArticleIdList": ["10.1038/oncsis.2015.28", "PMC4632089", "26436951"]}, {"Citation": "Chalhoub N, Baker SJ. PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol (2009) 4:127\u201350. doi: 10.1146/annurev.pathol.4.110807.092311", "ArticleIdList": ["10.1146/annurev.pathol.4.110807.092311", "PMC2710138", "18767981"]}, {"Citation": "Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, et al. . Mammalian Target of Rapamycin Activator RHEB is Frequently Overexpressed in Human Carcinomas and is Critical and sufficient for Skin Epithelial Carcinogenesis. Cancer Res (2010) 70(8):3287\u201398. doi: 10.1158/0008-5472.CAN-09-3467", "ArticleIdList": ["10.1158/0008-5472.CAN-09-3467", "PMC2855737", "20388784"]}, {"Citation": "Lee CH, Inoki K, Karbowniczek M, Petroulakis E, Sonenberg N, Henske EP, et al. . Constitutive mTOR Activation in TSC Mutants Sensitizes Cells to Energy Starvation and Genomic Damage via p53. EMBO J (2007) 26(23):4812\u201323. doi: 10.1038/sj.emboj.7601900", "ArticleIdList": ["10.1038/sj.emboj.7601900", "PMC2099465", "17962806"]}, {"Citation": "Zhang S, Hu B, Lv X, Chen S, Liu W, Shao Z. The Prognostic Role of Ribosomal Protein S6 Kinase 1 Pathway in Patients With Solid Tumors: A Meta-Analysis. Front Oncol (2019) 9:390. doi: 10.3389/fonc.2019.00390", "ArticleIdList": ["10.3389/fonc.2019.00390", "PMC6527894", "31139572"]}, {"Citation": "Van der Hage J, van den Broek L, Legrand C, Clahsen P, Bosch C, Robanus-Maandag E, et al. . Overexpression of P70 S6 Kinase Protein is Associated with Increased Risk of Locoregional Recurrence in Node-negative Premenopausal early Breast Cancer Patients. Br J Cancer (2004) 90(8):1543\u201350. doi: 10.1038/sj.bjc.6601741", "ArticleIdList": ["10.1038/sj.bjc.6601741", "PMC2409704", "15083183"]}, {"Citation": "Musa J, Orth M, Dallmayer M, Baldauf M, Pardo C, Rotblat B, et al. . Eukaryotic Initiation Factor 4E-binding Protein 1 (4E-BP1): A Master Regulator of mRNA Translation Involved in Tumorigenesis. Oncogene (2016) 35(36):4675\u201388. doi: 10.1038/onc.2015.515", "ArticleIdList": ["10.1038/onc.2015.515", "26829052"]}, {"Citation": "Karlsson E, P\u00e9rez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, et al. . The mTOR Effectors 4EBP1 and S6K2 are Frequently Coexpressed, and Associated with a Poor Prognosis and Endocrine Resistance in Breast Cancer: A Retrospective Study Including Patients from the Randomised Stockholm Tamoxifen Trials. Breast Cancer Res (2013) 15(5):1\u201314. doi: 10.1186/bcr3557", "ArticleIdList": ["10.1186/bcr3557", "PMC3978839", "24131622"]}, {"Citation": "Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, et al. . 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. Cancer Res (2019) 79(7):1438\u201350. doi: 10.1158/0008-5472.CAN-18-1220", "ArticleIdList": ["10.1158/0008-5472.CAN-18-1220", "PMC6445709", "30894372"]}, {"Citation": "Qin X, Jiang B, Zhang Y. 4E-BP1, a multifactor regulated multifunctional protein. Cell Cycle (2016) 15(6):781\u20136. doi: 10.1080/15384101.2016.1151581", "ArticleIdList": ["10.1080/15384101.2016.1151581", "PMC4845917", "26901143"]}, {"Citation": "Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. . A Diverse Array of Cancer-Associated MTOR Mutations are Hyperactivating and can Predict Rapamycin Sensitivity. Cancer Discovery (2014) 4:554\u201363. doi: 10.1158/2159-8290.CD-13-0929", "ArticleIdList": ["10.1158/2159-8290.CD-13-0929", "PMC4012430", "24631838"]}, {"Citation": "Pilotto S, Simbolo M, Sperduti I, Novello S, Vicentini C, Peretti U, et al. . OA06. 06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). J Thorac Oncol (2017) 12:S266\u20137. doi: 10.1016/j.jtho.2016.11.260", "ArticleIdList": ["10.1016/j.jtho.2016.11.260"]}, {"Citation": "Lien EC, Lyssiotis CA, Cantley LC. Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. Metab Cancer (2016) 207:39\u201372. doi: 10.1007/978-3-319-42118-6_3", "ArticleIdList": ["10.1007/978-3-319-42118-6_3", "27557534"]}, {"Citation": "Csibi A, Lee G, Yoon S-O, Tong H, Ilter D, Elia I, et al. . The Mtorc1/S6K1 Pathway Regulates Glutamine Metabolism Through the Eif4b-Dependent Control of C-Myc Translation. Curr Biol (2014) 24:2274\u201380. doi: 10.1016/j.cub.2014.08.007", "ArticleIdList": ["10.1016/j.cub.2014.08.007", "PMC4190129", "25220053"]}, {"Citation": "Csibi A, Fendt S-M, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. . The Mtorc1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4. Cell (2013) 153:840\u201354. doi: 10.1016/j.cell.2013.04.023", "ArticleIdList": ["10.1016/j.cell.2013.04.023", "PMC3684628", "23663782"]}, {"Citation": "Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. science (2009) 324:1029\u201333. doi: 10.1126/science.1160809", "ArticleIdList": ["10.1126/science.1160809", "PMC2849637", "19460998"]}, {"Citation": "Buller CL, Loberg RD, Fan M-H, Zhu Q, Park JL, Vesely E, et al. . A GSK-3/TSC2/mTOR Pathway Regulates Glucose Uptake and GLUT1 Glucose Transporter Expression. Am J Physiology-Cell Physiol (2008) 295:C836\u201343. doi: 10.1152/ajpcell.00554.2007", "ArticleIdList": ["10.1152/ajpcell.00554.2007", "PMC2544442", "18650261"]}, {"Citation": "Gordan JD, Thompson CB, Simon MC. HIF and C-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and Proliferation. Cancer Cell (2007) 12:108\u201313. doi: 10.1016/j.ccr.2007.07.006", "ArticleIdList": ["10.1016/j.ccr.2007.07.006", "PMC3215289", "17692803"]}, {"Citation": "Menendez JA, Lupu R. Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis. Nat Rev Cancer (2007) 7:763\u201377. doi: 10.1038/nrc2222", "ArticleIdList": ["10.1038/nrc2222", "17882277"]}, {"Citation": "Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. . Akt Stimulates Hepatic SREBP1c and Lipogenesis Through Parallel Mtorc1-Dependent and Independent Pathways. Cell Metab (2011) 14:21\u201332. doi: 10.1016/j.cmet.2011.06.002", "ArticleIdList": ["10.1016/j.cmet.2011.06.002", "PMC3652544", "21723501"]}, {"Citation": "Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, et al. . Hepatic Mtorc2 Activates Glycolysis and Lipogenesis Through Akt, Glucokinase, and SREBP1c. Cell Metab (2012) 15:725\u201338. doi: 10.1016/j.cmet.2012.03.015", "ArticleIdList": ["10.1016/j.cmet.2012.03.015", "22521878"]}, {"Citation": "Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, et al. . Mtorc2 Activity is Elevated in Gliomas and Promotes Growth and Cell Motility via Overexpression of Rictor. Cancer Res (2007) 67:11712\u201320. doi: 10.1158/0008-5472.CAN-07-2223", "ArticleIdList": ["10.1158/0008-5472.CAN-07-2223", "18089801"]}, {"Citation": "Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. . mTOR Complex 2 is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice. Cancer Cell (2009) 15:148\u201359. doi: 10.1016/j.ccr.2008.12.017", "ArticleIdList": ["10.1016/j.ccr.2008.12.017", "PMC2701381", "19185849"]}, {"Citation": "Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, et al. . Mtorc2 Signaling Drives the Development and Progression of Pancreatic Cancer. Cancer Res (2016) 76:6911\u201323. doi: 10.1158/0008-5472.CAN-16-0810", "ArticleIdList": ["10.1158/0008-5472.CAN-16-0810", "PMC5135633", "27758884"]}, {"Citation": "Bian Y, Wang Z, Xu J, Zhao W, Cao H, Zhang Z. Elevated Rictor Expression is Associated With Tumor Progression and Poor Prognosis in Patients With Gastric Cancer. Biochem Biophys Res Commun (2015) 464:534\u201340. doi: 10.1016/j.bbrc.2015.07.001", "ArticleIdList": ["10.1016/j.bbrc.2015.07.001", "26159923"]}, {"Citation": "Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, et al. . mTOR Complex Component Rictor Interacts With Pkc\u03b6 and Regulates Cancer Cell Metastasis. Cancer Res (2010) 70:9360\u201370. doi: 10.1158/0008-5472.CAN-10-0207", "ArticleIdList": ["10.1158/0008-5472.CAN-10-0207", "20978191"]}, {"Citation": "Li H, Lin J, Wang X, Yao G, Wang L, Zheng H, et al. . Targeting of Mtorc2 Prevents Cell Migration and Promotes Apoptosis in Breast Cancer. Breast Cancer Res Treat (2012) 134:1057\u201366. doi: 10.1007/s10549-012-2036-2", "ArticleIdList": ["10.1007/s10549-012-2036-2", "22476852"]}, {"Citation": "Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al. . Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer. Clin Cancer Res (2009) 15:7207\u201316. doi: 10.1158/1078-0432.CCR-09-1249", "ArticleIdList": ["10.1158/1078-0432.CCR-09-1249", "PMC2898570", "19934294"]}, {"Citation": "Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, et al. . Glucose-Dependent Acetylation of Rictor Promotes Targeted Cancer Therapy Resistance. Proc Natl Acad Sci USA (2015) 112:9406\u201311. doi: 10.1073/pnas.1511759112", "ArticleIdList": ["10.1073/pnas.1511759112", "PMC4522814", "26170313"]}, {"Citation": "Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, et al. . Mtorc2 Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell (2017) 32:807\u2013823. e812. doi: 10.1016/j.ccell.2017.11.011", "ArticleIdList": ["10.1016/j.ccell.2017.11.011", "29232555"]}, {"Citation": "Li H, Fan X, Houghton J. Tumor Microenvironment: The Role of the Tumor Stroma in Cancer. J Cell Biochem (2007) 101:805\u201315. doi: 10.1002/jcb.21159", "ArticleIdList": ["10.1002/jcb.21159", "17226777"]}, {"Citation": "Balkwill FR, Capasso M, Hagemann T. The Tumor Microenvironment at a Glance. J Cell Sci (2012) 125(Pt 23):5591\u20136. doi: 10.1242/jcs.116392", "ArticleIdList": ["10.1242/jcs.116392", "23420197"]}, {"Citation": "Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR Kinase Determines Effector Versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-Bet and Eomesodermin. Immunity (2010) 32:67\u201378. doi: 10.1016/j.immuni.2009.10.010", "ArticleIdList": ["10.1016/j.immuni.2009.10.010", "PMC5836496", "20060330"]}, {"Citation": "Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. . The Kinase mTOR Regulates the Differentiation of Helper T Cells Through the Selective Activation of Signaling by Mtorc1 and Mtorc2. Nat Immunol (2011) 12:295. doi: 10.1038/ni.2005", "ArticleIdList": ["10.1038/ni.2005", "PMC3077821", "21358638"]}, {"Citation": "Kim EH, Suresh M. Role of PI3K/Akt Signaling in Memory CD8 T Cell Differentiation. Front Immunol (2013) 4:20. doi: 10.3389/fimmu.2013.00020", "ArticleIdList": ["10.3389/fimmu.2013.00020", "PMC3561661", "23378844"]}, {"Citation": "Chi H. Regulation and Function of mTOR Signalling in T Cell Fate Decisions. Nat Rev Immunol (2012) 12:325\u201338. doi: 10.1038/nri3198", "ArticleIdList": ["10.1038/nri3198", "PMC3417069", "22517423"]}, {"Citation": "Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. . mTOR Regulates Memory CD8 T-Cell Differentiation. Nature (2009) 460:108\u201312. doi: 10.1038/nature08155", "ArticleIdList": ["10.1038/nature08155", "PMC2710807", "19543266"]}, {"Citation": "Bantug GR, Galluzzi L, Kroemer G, Hess C. The Spectrum of T Cell Metabolism in Health and Disease. Nat Rev Immunol (2018) 18:19. doi: 10.1038/nri.2017.99", "ArticleIdList": ["10.1038/nri.2017.99", "28944771"]}, {"Citation": "Chang CH, Qiu J, O\u2019sullivan D, Buck MD, Noguchi T, Curtis JD, et al. . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 162:1229\u201341. doi: 10.1016/j.cell.2015.08.016", "ArticleIdList": ["10.1016/j.cell.2015.08.016", "PMC4864363", "26321679"]}, {"Citation": "Sun X, Wang M, Wang M, Yao L, Li X, Dong H, et al. . Role of Proton-Coupled Monocarboxylate Transporters in Cancer: From Metabolic Crosstalk to Therapeutic Potential. Front Cell Dev Biol (2020) 8:651. doi: 10.3389/fcell.2020.00651", "ArticleIdList": ["10.3389/fcell.2020.00651", "PMC7379837", "32766253"]}, {"Citation": "Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. . Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-Tumor T Cell Responses. Cell (2015) 162:1217\u201328. doi: 10.1016/j.cell.2015.08.012", "ArticleIdList": ["10.1016/j.cell.2015.08.012", "PMC4567953", "26321681"]}, {"Citation": "Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. . The CD28 Signaling Pathway Regulates Glucose Metabolism. Immunity (2002) 16:769\u201377. doi: 10.1016/S1074-7613(02)00323-0", "ArticleIdList": ["10.1016/S1074-7613(02)00323-0", "12121659"]}, {"Citation": "Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. . CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Mol Cell Biol (2005) 25:9543\u201353. doi: 10.1128/MCB.25.21.9543-9553.2005", "ArticleIdList": ["10.1128/MCB.25.21.9543-9553.2005", "PMC1265804", "16227604"]}, {"Citation": "Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. . PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res (2014) 2:361\u201370. doi: 10.1158/2326-6066.CIR-13-0127", "ArticleIdList": ["10.1158/2326-6066.CIR-13-0127", "PMC4000553", "24764583"]}, {"Citation": "Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. . Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape. Mol Cancer (2019) 18:10. doi: 10.1186/s12943-018-0928-4", "ArticleIdList": ["10.1186/s12943-018-0928-4", "PMC6332843", "30646912"]}, {"Citation": "Cornish GH, Sinclair LV, Cantrell DA. Differential Regulation of T-Cell Growth by IL-2 and IL-15. Blood (2006) 108:600\u20138. doi: 10.1182/blood-2005-12-4827", "ArticleIdList": ["10.1182/blood-2005-12-4827", "16569767"]}, {"Citation": "Ray JP, Staron MM, Shyer JA, Ho PC, Marshall HD, Gray SM, et al. . The Interleukin-2-Mtorc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. Immunity (2015) 43:690\u2013702. doi: 10.1016/j.immuni.2015.08.017", "ArticleIdList": ["10.1016/j.immuni.2015.08.017", "PMC4618086", "26410627"]}, {"Citation": "Ong ST, Ng AS, Ng XR, Zhuang Z, Wong BHS, Prasannan P, et al. . Extracellular K+ Dampens T Cell Functions: Implications for Immune Suppression in the Tumor Microenvironment. Bioelectricity (2019) 1:169\u201379. doi: 10.1089/bioe.2019.0016", "ArticleIdList": ["10.1089/bioe.2019.0016", "PMC8370284", "34471819"]}, {"Citation": "Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, et al. . Ionic Immune Suppression Within the Tumour Microenvironment Limits T Cell Effector Function. Nature (2016) 537:539\u201343. doi: 10.1038/nature19364", "ArticleIdList": ["10.1038/nature19364", "PMC5204372", "27626381"]}, {"Citation": "Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. . Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discovery (2016) 6:202\u201316. doi: 10.1158/2159-8290.CD-15-0283", "ArticleIdList": ["10.1158/2159-8290.CD-15-0283", "PMC4744499", "26645196"]}, {"Citation": "Ananieva EA, Patel CH, Drake CH, Powell JD, Hutson SM. Cytosolic Branched Chain Aminotransferase (BCATc) Regulates Mtorc1 Signaling and Glycolytic Metabolism in CD4+ T Cells. J Biol Chem (2014) 289:18793\u2013804. doi: 10.1074/jbc.M114.554113", "ArticleIdList": ["10.1074/jbc.M114.554113", "PMC4081922", "24847056"]}, {"Citation": "Nakaya M, Xiao Y, Zhou X, Chang J-H, Chang M, Cheng X, et al. . Inflammatory T Cell Responses Rely on Amino Acid Transporter ASCT2 Facilitation of Glutamine Uptake and Mtorc1 Kinase Activation. Immunity (2014) 40:692\u2013705. doi: 10.1016/j.immuni.2014.04.007", "ArticleIdList": ["10.1016/j.immuni.2014.04.007", "PMC4074507", "24792914"]}, {"Citation": "Nguyen TP, Frank AR, Jewell JL. Amino Acid and Small GTPase Regulation of Mtorc1. Cell Logist (2017) 7:e1378794. doi: 10.1080/21592799.2017.1378794", "ArticleIdList": ["10.1080/21592799.2017.1378794", "PMC5739091", "29296509"]}, {"Citation": "Zhang Y, Hu H, Liu W, Yan S-M, Li Y, Tan L, et al. . Amino Acids and RagD Potentiate Mtorc1 Activation in CD8+ T Cells to Confer Antitumor Immunity. J Immunother Cancer (2021) 9:e002137. doi: 10.1136/jitc-2020-002137", "ArticleIdList": ["10.1136/jitc-2020-002137", "PMC8061841", "33883257"]}, {"Citation": "Timosenko E, Hadjinicolaou AV, Cerundolo V. Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes. Immunotherapy (2017) 9:83\u201397. doi: 10.2217/imt-2016-0118", "ArticleIdList": ["10.2217/imt-2016-0118", "28000524"]}, {"Citation": "Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 23:27\u201347. doi: 10.1016/j.cmet.2015.12.006", "ArticleIdList": ["10.1016/j.cmet.2015.12.006", "PMC4715268", "26771115"]}, {"Citation": "Sang Y, Kong P, Zhang S, Zhang L, Cao Y, Duan X, et al. . SGK1 in Human Cancer: Emerging Roles and Mechanisms. Front Oncol (2021) 10:2987. doi: 10.3389/fonc.2020.608722", "ArticleIdList": ["10.3389/fonc.2020.608722", "PMC7851074", "33542904"]}, {"Citation": "Kovacevic Z, Richardson DRJC. The Metastasis Suppressor, Ndrg-1: A New Ally in the Fight Against Cancer. Carcinogenesis (2006) 27:2355\u201366. doi: 10.1093/carcin/bgl146", "ArticleIdList": ["10.1093/carcin/bgl146", "16920733"]}, {"Citation": "Murakami Y, Watari K, Shibata T, Uba M, Ureshino H, Kawahara A, et al. . N-Myc Downstream-Regulated Gene 1 Promotes Tumor Inflammatory Angiogenesis Through JNK Activation and Autocrine Loop of Interleukin-1\u03b1 by Human Gastric Cancer Cells. J Biol Chem (2013) 288:25025\u201337. doi: 10.1074/jbc.M113.472068", "ArticleIdList": ["10.1074/jbc.M113.472068", "PMC3757168", "23846687"]}, {"Citation": "Dolati S, Babaloo Z, Ayromlou H, Ahmadi M, Rikhtegar R, Rostamzadeh D, et al. . Nanocurcumin Improves Regulatory T-Cell Frequency and Function in Patients With Multiple Sclerosis. J Neuroimmunol (2019) 327:15\u201321. doi: 10.1016/j.jneuroim.2019.01.007", "ArticleIdList": ["10.1016/j.jneuroim.2019.01.007", "30683426"]}, {"Citation": "Togashi Y, Shitara K, Nishikawa H. Regulatory T Cells in Cancer Immunosuppression\u2014Implications for Anticancer Therapy. Nat Rev Clin Oncol (2019) 16:356\u201371. doi: 10.1038/s41571-019-0175-7", "ArticleIdList": ["10.1038/s41571-019-0175-7", "30705439"]}, {"Citation": "Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory Functions of mTOR Inhibition. Nat Rev Immunol (2009) 9:324\u201337. doi: 10.1038/nri2546", "ArticleIdList": ["10.1038/nri2546", "PMC2847476", "19390566"]}, {"Citation": "Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, et al. . PI3K-Akt-Mtorc1-S6K1/2 Axis Controls Th17 Differentiation by Regulating Gfi1 Expression and Nuclear Translocation of Ror\u03b3. Cell Rep (2012) 1:360\u201373. doi: 10.1016/j.celrep.2012.02.007", "ArticleIdList": ["10.1016/j.celrep.2012.02.007", "22832227"]}, {"Citation": "Kishore M, Cheung KC, Fu H, Bonacina F, Wang G, Coe D, et al. . Regulatory T Cell Migration is Dependent on Glucokinase-Mediated Glycolysis. Immunity (2017) 47:875\u2013889. e810. doi: 10.1016/j.immuni.2017.10.017", "ArticleIdList": ["10.1016/j.immuni.2017.10.017", "PMC5714502", "29166588"]}, {"Citation": "Gerriets VA, Kishton RJ, Johnson MO, Cohen S, Siska PJ, Nichols AG, et al. . Foxp3 and Toll-Like Receptor Signaling Balance T Reg Cell Anabolic Metabolism for Suppression. Nat Immunol (2016) 17:1459\u201366. doi: 10.1038/ni.3577", "ArticleIdList": ["10.1038/ni.3577", "PMC5215903", "27695003"]}, {"Citation": "Hardie DG. AMP-Activated Protein Kinase: An Energy Sensor That Regulates All Aspects of Cell Function. Genes Dev (2011) 25:1895\u2013908. doi: 10.1101/gad.17420111", "ArticleIdList": ["10.1101/gad.17420111", "PMC3185962", "21937710"]}, {"Citation": "Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. . PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells. J Exp Med (2009) 206:3015\u201329. doi: 10.1084/jem.20090847", "ArticleIdList": ["10.1084/jem.20090847", "PMC2806460", "20008522"]}, {"Citation": "Sun IH, Oh MH, Zhao L, Patel CH, Arwood ML, Xu W, et al. . mTOR Complex 1 Signaling Regulates the Generation and Function of Central and Effector Foxp3(+) Regulatory T Cells. J Immunol (2018) 201:481\u201392. doi: 10.4049/jimmunol.1701477", "ArticleIdList": ["10.4049/jimmunol.1701477", "PMC6089237", "29884702"]}, {"Citation": "Lastwika KJ, Wilson W, 3rd, Li QK, Norris J, Xu H, Ghazarian SR, et al. . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res (2016) 76:227\u201338. doi: 10.1158/0008-5472.CAN-14-3362", "ArticleIdList": ["10.1158/0008-5472.CAN-14-3362", "26637667"]}, {"Citation": "Sinclair LV, Rolf J, Emslie E, Shi Y-B, Taylor PM, Cantrell DA. Control of Amino-Acid Transport by Antigen Receptors Coordinates the Metabolic Reprogramming Essential for T Cell Differentiation. Nat Immunol (2013) 14:500. doi: 10.1038/ni.2556", "ArticleIdList": ["10.1038/ni.2556", "PMC3672957", "23525088"]}, {"Citation": "Patel CH, Powell JD. Targeting T Cell Metabolism to Regulate T Cell Activation, Differentiation and Function in Disease. Curr Opin Immunol (2017) 46:82\u20138. doi: 10.1016/j.coi.2017.04.006", "ArticleIdList": ["10.1016/j.coi.2017.04.006", "PMC5554728", "28521236"]}, {"Citation": "Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RD, Mcarthur GA. Translational Control of C-MYC by Rapamycin Promotes Terminal Myeloid Differentiation. J Am Soc Hematol (2008) 112:2305\u201317. doi: 10.1182/blood-2007-09-111856", "ArticleIdList": ["10.1182/blood-2007-09-111856", "18621930"]}, {"Citation": "Babcock JT, Nguyen HB, He Y, Hendricks JW, Wek RC, Quilliam LA. Mammalian Target of Rapamycin Complex 1 (Mtorc1) Enhances Bortezomib-Induced Death in Tuberous Sclerosis Complex (TSC)-Null Cells by a C-MYC-Dependent Induction of the Unfolded Protein Response. J Biol Chem (2013) 288:15687\u201398. doi: 10.1074/jbc.M112.431056", "ArticleIdList": ["10.1074/jbc.M112.431056", "PMC3668728", "23612979"]}, {"Citation": "Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, et al. . Glutamine-Dependent \u03b1-Ketoglutarate Production Regulates the Balance Between T Helper 1 Cell and Regulatory T Cell Generation. Sci Signal (2015) 8:ra97\u20137. doi: 10.1126/scisignal.aab2610", "ArticleIdList": ["10.1126/scisignal.aab2610", "26420908"]}, {"Citation": "Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. . L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-Tumor Activity. Cell (2016) 167:829\u2013842 e813. doi: 10.1016/j.cell.2016.09.031", "ArticleIdList": ["10.1016/j.cell.2016.09.031", "PMC5075284", "27745970"]}, {"Citation": "Gabrilovich DI, Nagaraj S. Myeloid-Derived Suppressor Cells as Regulators of the Immune System. Nat Rev Immunol (2009) 9:162\u201374. doi: 10.1038/nri2506", "ArticleIdList": ["10.1038/nri2506", "PMC2828349", "19197294"]}, {"Citation": "Bronte V, Zanovello P. Regulation of Immune Responses by L-Arginine Metabolism. Nat Rev Immunol (2005) 5:641\u201354. doi: 10.1038/nri1668", "ArticleIdList": ["10.1038/nri1668", "16056256"]}, {"Citation": "Saqib U, Sarkar S, Suk K, Mohammad O, Baig MS, Savai R. Phytochemicals as Modulators of M1-M2 Macrophages in Inflammation. Oncotarget (2018) 9:17937\u201350. doi: 10.18632/oncotarget.24788", "ArticleIdList": ["10.18632/oncotarget.24788", "PMC5915167", "29707159"]}, {"Citation": "Balkwill F, Charles KA, Mantovani AJCC. Smoldering and Polarized Inflammation in the Initiation and Promotion of Malignant Disease. Cancer Cell (2005) 7:211\u20137. doi: 10.1016/j.ccr.2005.02.013", "ArticleIdList": ["10.1016/j.ccr.2005.02.013", "15766659"]}, {"Citation": "Biswas SK, Allavena P, Mantovani A. Tumor-Associated Macrophages: Functional Diversity, Clinical Significance, and Open Questions. Semin Immunopathol (2013) 35:585\u2013600. doi: 10.1007/s00281-013-0367-7", "ArticleIdList": ["10.1007/s00281-013-0367-7", "23657835"]}, {"Citation": "Covarrubias AJ, Aksoylar HI, Horng T. Control of Macrophage Metabolism and Activation by mTOR and Akt Signaling. Semin Immunol (2015) 27:286\u201396. doi: 10.1016/j.smim.2015.08.001", "ArticleIdList": ["10.1016/j.smim.2015.08.001", "PMC4682888", "26360589"]}, {"Citation": "Yang CS, Song CH, Lee JS, Jung SB, Oh JH, Park J, et al. . Intracellular Network of Phosphatidylinositol 3-Kinase, Mammalian Target of the Rapamycin/70 kDa Ribosomal S6 Kinase 1, and Mitogen-Activated Protein Kinases Pathways for Regulating Mycobacteria-Induced IL-23 Expression in Human Macrophages. Cell Micribiol (2006) 8:1158\u201371. doi: 10.1111/j.1462-5822.2006.00699.x", "ArticleIdList": ["10.1111/j.1462-5822.2006.00699.x", "16819968"]}, {"Citation": "Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, et al. . Rapamycin Unbalances the Polarization of Human Macrophages to M 1. Immunology (2013) 140:179\u201390. doi: 10.1111/imm.12126", "ArticleIdList": ["10.1111/imm.12126", "PMC3784164", "23710834"]}, {"Citation": "Chen W, Ma T, Shen X-N, Xia X-F, Xu G-D, Bai X-L, et al. . Macrophage-Induced Tumor Angiogenesis is Regulated by the TSC2\u2013mTOR Pathway. Cancer Res (2012) 72:1363\u201372. doi: 10.1158/0008-5472.CAN-11-2684", "ArticleIdList": ["10.1158/0008-5472.CAN-11-2684", "22287548"]}, {"Citation": "Yang Z, Xie H, He D, Li L. Infiltrating Macrophages Increase RCC Epithelial Mesenchymal Transition (EMT) and Stem Cell-Like Populations via AKT and mTOR Signaling. Oncotarget (2016) 7:44478\u201391. doi: 10.18632/oncotarget.9873", "ArticleIdList": ["10.18632/oncotarget.9873", "PMC5190112", "27283897"]}, {"Citation": "Zheng P, Luo Q, Wang W, Li J, Wang T, Wang P, et al. . Tumor-Associated Macrophages-Derived Exosomes Promote the Migration of Gastric Cancer Cells by Transfer of Functional Apolipoprotein E. Cell Death Dis (2018) 9:1\u201314. doi: 10.1038/s41419-018-0465-5", "ArticleIdList": ["10.1038/s41419-018-0465-5", "PMC5864742", "29567987"]}, {"Citation": "Jha AK, Huang SC-C, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. . Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules That Regulate Macrophage Polarization. Immunity (2015) 42:419\u201330. doi: 10.1016/j.immuni.2015.02.005", "ArticleIdList": ["10.1016/j.immuni.2015.02.005", "25786174"]}, {"Citation": "Huang SC-C, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. . Metabolic Reprogramming Mediated by the Mtorc2-IRF4 Signaling Axis is Essential for Macrophage Alternative Activation. Immunity (2016) 45:817\u201330. doi: 10.1016/j.immuni.2016.09.016", "ArticleIdList": ["10.1016/j.immuni.2016.09.016", "PMC5535820", "27760338"]}, {"Citation": "D\u00edaz-Vald\u00e9s N, Basagoiti M, Dotor J, Aranda F, Monreal I, Riezu-Boj JI, et al. . Induction of Monocyte Chemoattractant Protein-1 and Interleukin-10 by Tgf\u03b21 in Melanoma Enhances Tumor Infiltration and Immunosuppression. Cancer Res (2011) 71:812\u201321. doi: 10.1158/0008-5472.CAN-10-2698", "ArticleIdList": ["10.1158/0008-5472.CAN-10-2698", "21159663"]}, {"Citation": "Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, et al. . T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 30:377\u201390. doi: 10.1016/j.ccell.2016.08.004", "ArticleIdList": ["10.1016/j.ccell.2016.08.004", "PMC5023283", "27622331"]}, {"Citation": "Alderton WK, Cooper CE, Knowles RG. Nitric Oxide Synthases: Structure, Function and Inhibition. Biochem J (2001) 357:593\u2013615. doi: 10.1042/bj3570593", "ArticleIdList": ["10.1042/bj3570593", "PMC1221991", "11463332"]}, {"Citation": "Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. . Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. Cancer Res (2004) 64:5839\u201349. doi: 10.1158/0008-5472.CAN-04-0465", "ArticleIdList": ["10.1158/0008-5472.CAN-04-0465", "15313928"]}, {"Citation": "Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. . Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. Cancer Res (2005) 65:3044\u20138. doi: 10.1158/0008-5472.CAN-04-4505", "ArticleIdList": ["10.1158/0008-5472.CAN-04-4505", "15833831"]}, {"Citation": "Rodriguez PC, Quiceno DG, Ochoa AC. L-Arginine Availability Regulates T-Lymphocyte Cell-Cycle Progression. Blood (2007) 109:1568\u201373. doi: 10.1182/blood-2006-06-031856", "ArticleIdList": ["10.1182/blood-2006-06-031856", "PMC1794048", "17023580"]}, {"Citation": "Rodriguez PC, Hernandez CP, Morrow K, Sierra R, Zabaleta J, Wyczechowska DD, et al. . L-Arginine Deprivation Regulates Cyclin D3 mRNA Stability in Human T Cells by Controlling HuR Expression. J Immunol (2010) 185:5198\u2013204. doi: 10.4049/jimmunol.1001224", "ArticleIdList": ["10.4049/jimmunol.1001224", "PMC3108892", "20889542"]}, {"Citation": "Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y, et al. . Tumor-Associated Macrophages Secrete CC-Chemokine Ligand 2 and Induce Tamoxifen Resistance by Activating PI3K/Akt/mTOR in Breast Cancer. Cancer Sci (2020) 111:47\u201358. doi: 10.1111/cas.14230", "ArticleIdList": ["10.1111/cas.14230", "PMC6942430", "31710162"]}, {"Citation": "Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, et al. . Akt-Mtorc1 Signaling Regulates Acly to Integrate Metabolic Input to Control of Macrophage Activation. elife (2016) 5:e11612. doi: 10.7554/eLife.11612", "ArticleIdList": ["10.7554/eLife.11612", "PMC4769166", "26894960"]}, {"Citation": "Park JE, Dutta B, Tse SW, Gupta N, Tan CF, Low JK, et al. . Hypoxia-Induced Tumor Exosomes Promote M2-Like Macrophage Polarization of Infiltrating Myeloid Cells and microRNA-Mediated Metabolic Shift. Oncogene (2019) 26:5158\u201373. doi: 10.1038/s41388-019-0782-x", "ArticleIdList": ["10.1038/s41388-019-0782-x", "30872795"]}, {"Citation": "Wang W, Liu Y, Guo J, He H, Mi X, Chen C, et al. . miR-100 Maintains Phenotype of Tumor-Associated Macrophages by Targeting mTOR to Promote Tumor Metastasis via Stat5a/IL-1ra Pathway in Mouse Breast Cancer. Oncogenesis (2018) 7:97. doi: 10.1038/s41389-018-0106-y", "ArticleIdList": ["10.1038/s41389-018-0106-y", "PMC6299090", "30563983"]}, {"Citation": "Yang Y, Alderman C, Sehlaoui A, Xiao Y, Wang W. MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. Can J Gastroenterol Hepatol (2018) 2018:9740357. doi: 10.1155/2018/9740357", "ArticleIdList": ["10.1155/2018/9740357", "PMC6038585", "30046565"]}, {"Citation": "Wenes M, Shang M, Di Matteo M, Goveia J, Mart\u00edn-P\u00e9rez R, Serneels J, et al. . Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. Cell Metab (2016) 24:701\u201315. doi: 10.1016/j.cmet.2016.09.008", "ArticleIdList": ["10.1016/j.cmet.2016.09.008", "27773694"]}, {"Citation": "Deng Y, Yang J, Luo F, Qian J, Liu R, Zhang D, et al. . mTOR-Mediated Glycolysis Contributes to the Enhanced Suppressive Function of Murine Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells. Cancer Immunol Immunother (2018) 67:1355\u201364. doi: 10.1007/s00262-018-2177-1", "ArticleIdList": ["10.1007/s00262-018-2177-1", "29968153"]}, {"Citation": "Tesi R. MDSC; the Most Important Cell You Have Never Heard of. Trends Pharmacol Sci (2019) 40:4\u20137. doi: 10.1016/j.tips.2018.10.008", "ArticleIdList": ["10.1016/j.tips.2018.10.008", "30527590"]}, {"Citation": "Wu T, Zhao Y, Wang H, Li Y, Shao L, Wang R, et al. . mTOR Masters Monocytic Myeloid-Derived Suppressor Cells in Mice With Allografts or Tumors. Sci Rep (2016) 6:20250. doi: 10.1038/srep20250", "ArticleIdList": ["10.1038/srep20250", "PMC4735296", "26833095"]}, {"Citation": "Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, et al. . Oncogenic mTOR Signalling Recruits Myeloid-Derived Suppressor Cells to Promote Tumour Initiation. Nat Cell Biol (2016) 18:632\u201344. doi: 10.1038/ncb3355", "ArticleIdList": ["10.1038/ncb3355", "PMC4884142", "27183469"]}, {"Citation": "Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P, et al. . Role of TGF-\u03b2 Signaling in Generation of CD39+ CD73+ Myeloid Cells in Tumors. J Immunol (2014) 193:3155\u201364. doi: 10.4049/jimmunol.1400578", "ArticleIdList": ["10.4049/jimmunol.1400578", "PMC4157098", "25127858"]}, {"Citation": "Li J, Wang L, Chen X, Li L, Li Y, Ping Y, et al. . CD39/CD73 Upregulation on Myeloid-Derived Suppressor Cells via TGF-beta-mTOR-HIF-1 Signaling in Patients With Non-Small Cell Lung Cancer. Oncoimmunology (2017) 6:e1320011. doi: 10.1080/2162402X.2017.1320011", "ArticleIdList": ["10.1080/2162402X.2017.1320011", "PMC5486179", "28680754"]}, {"Citation": "Raber PL, Sierra RA, Thevenot PT, Shuzhong Z, Wyczechowska DD, Kumai T, et al. . T Cells Conditioned With MDSC Show an Increased Anti-Tumor Activity After Adoptive T Cell Based Immunotherapy. Oncotarget (2016) 7:17565\u201378. doi: 10.18632/oncotarget.8197", "ArticleIdList": ["10.18632/oncotarget.8197", "PMC4951233", "27007050"]}, {"Citation": "Mei S, Xin J, Liu Y, Zhang Y, Liang X, Su X, et al. . MicroRNA-200c Promotes Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating PTEN and FOG2 Expression. PloS One (2015) 10:e0135867. doi: 10.1371/journal.pone.0135867", "ArticleIdList": ["10.1371/journal.pone.0135867", "PMC4540422", "26285119"]}, {"Citation": "Shaul ME, Fridlender ZG. Tumour-Associated Neutrophils in Patients With Cancer. Nat Rev Clin Oncol (2019) 16:601\u201320. doi: 10.1038/s41571-019-0222-4", "ArticleIdList": ["10.1038/s41571-019-0222-4", "31160735"]}, {"Citation": "Liu L, Das S, Losert W, Parent CA. Mtorc2 Regulates Neutrophil Chemotaxis in a cAMP-And RhoA-Dependent Fashion. Dev Cell (2010) 19:845\u201357. doi: 10.1016/j.devcel.2010.11.004", "ArticleIdList": ["10.1016/j.devcel.2010.11.004", "PMC3071587", "21145500"]}, {"Citation": "Shrivastava R, Asif M, Singh V, Dubey P, Malik SA, Tewari BN, et al. . M2 Polarization of Macrophages by Oncostatin M in Hypoxic Tumor Microenvironment is Mediated by Mtorc2 and Promotes Tumor Growth and Metastasis. Cytokine (2019) 118:130\u201343. doi: 10.1016/j.cyto.2018.03.032", "ArticleIdList": ["10.1016/j.cyto.2018.03.032", "29625858"]}, {"Citation": "Li X-F, Chen D-P, Ouyang F-Z, Chen M-M, Wu Y, Kuang D-M, et al. . Increased Autophagy Sustains the Survival and Pro-Tumourigenic Effects of Neutrophils in Human Hepatocellular Carcinoma. J Hepatol (2015) 62:131\u20139. doi: 10.1016/j.jhep.2014.08.023", "ArticleIdList": ["10.1016/j.jhep.2014.08.023", "25152203"]}, {"Citation": "Wellenstein MD, De Visser KE. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity (2018) 48:399\u2013416. doi: 10.1016/j.immuni.2018.03.004", "ArticleIdList": ["10.1016/j.immuni.2018.03.004", "29562192"]}, {"Citation": "Gomez-Cambronero J. Rapamycin Inhibits GM-CSF-Induced Neutrophil Migration. FEBS Lett (2003) 550:94\u2013100. doi: 10.1016/S0014-5793(03)00828-7", "ArticleIdList": ["10.1016/S0014-5793(03)00828-7", "PMC3074563", "12935893"]}, {"Citation": "Chen YL, Lin HW, Sun NY, Yie JC, Hung HC, Chen CA, et al. . mTOR Inhibitors Can Enhance the Anti-Tumor Effects of DNA Vaccines Through Modulating Dendritic Cell Function in the Tumor Microenvironment. Cancers (Basel) (2019) 11:617\u201336. doi: 10.3390/cancers11050617", "ArticleIdList": ["10.3390/cancers11050617", "PMC6562783", "31052575"]}, {"Citation": "Raich-Regue D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW. Intratumoral Delivery of Mtorc2-Deficient Dendritic Cells Inhibits B16 Melanoma Growth by Promoting CD8(+) Effector T Cell Responses. Oncoimmunology (2016) 5:e1146841. doi: 10.1080/2162402X.2016.1146841", "ArticleIdList": ["10.1080/2162402X.2016.1146841", "PMC4938309", "27471613"]}, {"Citation": "Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, et al. . Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice. J Immunol (2012) 189:2151\u20138. doi: 10.4049/jimmunol.1103741", "ArticleIdList": ["10.4049/jimmunol.1103741", "PMC3424310", "22826320"]}, {"Citation": "Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. . The Metabolic Checkpoint Kinase mTOR is Essential for IL-15 Signaling During the Development and Activation of NK Cells. Nat Immunol (2014) 15:749\u201357. doi: 10.1038/ni.2936", "ArticleIdList": ["10.1038/ni.2936", "PMC4110708", "24973821"]}, {"Citation": "Viel S, Marcais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, et al. . TGF-Beta Inhibits the Activation and Functions of NK Cells by Repressing the mTOR Pathway. Sci Signal (2016) 9:ra19. doi: 10.1126/scisignal.aad1884", "ArticleIdList": ["10.1126/scisignal.aad1884", "26884601"]}, {"Citation": "Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, et al. . Hypoxia Downregulates the Expression of Activating Receptors Involved in NK-Cell-Mediated Target Cell Killing Without Affecting ADCC. Eur J Immunol (2013) 43:2756\u201364. doi: 10.1002/eji.201343448", "ArticleIdList": ["10.1002/eji.201343448", "23913266"]}, {"Citation": "Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. . Inhibition of Arginase by CB-1158 Blocks Myeloid Cell-Mediated Immune Suppression in the Tumor Microenvironment. J Immunother Cancer (2017) 5:101. doi: 10.1186/s40425-017-0308-4", "ArticleIdList": ["10.1186/s40425-017-0308-4", "PMC5735564", "29254508"]}, {"Citation": "Guo S, Huang C, Han F, Chen B, Ding Y, Zhao Y, et al. . Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function Through mTOR Signalling to Promote Tumour Growth. Stem Cells Int (2021) 2021:9989790. doi: 10.1155/2021/9989790", "ArticleIdList": ["10.1155/2021/9989790", "PMC8263240", "34306099"]}, {"Citation": "Felices M, Lenvik AJ, Mcelmurry R, Chu S, Hinderlie P, Bendzick L, et al. . Continuous Treatment With IL-15 Exhausts Human NK Cells via a Metabolic Defect. JCI Insight (2018) 3:e96219. doi: 10.1172/jci.insight.96219", "ArticleIdList": ["10.1172/jci.insight.96219", "PMC5821201", "29415897"]}, {"Citation": "Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, et al. . NKT Cells as an Ideal Anti-Tumor Immunotherapeutic. Front Immunol (2013) 4:409. doi: 10.3389/fimmu.2013.00409", "ArticleIdList": ["10.3389/fimmu.2013.00409", "PMC3845015", "24348476"]}, {"Citation": "Gupta S, Roy A, Dwarakanath BS. Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. Front Oncol (2017) 7:68. doi: 10.3389/fonc.2017.00068", "ArticleIdList": ["10.3389/fonc.2017.00068", "PMC5388702", "28447025"]}, {"Citation": "Yin Z, Bai L, Li W, Zeng T, Tian H, Cui J. Targeting T Cell Metabolism in the Tumor Microenvironment: An Anti-Cancer Therapeutic Strategy. J Exp Clin Cancer Res (2019) 38:403. doi: 10.1186/s13046-019-1409-3", "ArticleIdList": ["10.1186/s13046-019-1409-3", "PMC6743108", "31519198"]}, {"Citation": "Xie D, Zhu S, Bai L. Lactic Acid in Tumor Microenvironments Causes Dysfunction of NKT Cells by Interfering With mTOR Signaling. Sci China Life Sci (2016) 59:1290\u20136. doi: 10.1007/s11427-016-0348-7", "ArticleIdList": ["10.1007/s11427-016-0348-7", "27995420"]}, {"Citation": "Shin J, Wang S, Deng W, Wu J, Gao J, Zhong X-P. Mechanistic Target of Rapamycin Complex 1 Is Critical for Invariant Natural Killer T-Cell Development and Effector Function. PNAS (2014) 111:E776\u201383. doi: 10.1073/pnas.1315435111", "ArticleIdList": ["10.1073/pnas.1315435111", "PMC3939904", "24516149"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "9", "Day": "11"}, {"Year": "2021", "Month": "12", "Day": "14"}, {"Year": "2022", "Month": "3", "Day": "7", "Hour": "6", "Minute": "3"}, {"Year": "2022", "Month": "3", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["35250965", "PMC8894239", "10.3389/fimmu.2021.774103"]}}], "PubmedBookArticle": []}